Product Description
ANC-501 is a drug candidate for the treatment of major depressive disorder from Aditum Bio. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05439603)
Mechanisms of Action: V1b Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ANC501D0005 | P2 |
Completed |
Depressive Disorder, Major |
2023-08-14 |
47% |
2025-01-03 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/21/2022 |
News Article |
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression |
|
11/08/2021 |
News Article |
Aditum Bio announces the appointment of Stephen Kanes, M.D. Ph.D., as Chief Executive Officer of Ancora Bio |
|
06/30/2021 |
News Article |
Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment-Resistant Depression |